Checking These Areas for Lumps Can Help Catch Lymphoma Early

lymphomanewstoday.com
This video from TakeaPITStop uses a Barbie doll to demonstrate how lymphoma patients often discover their lumps.

 

This video from uses a Barbie doll to demonstrate how lymphoma patients often discover their lumps. During Barbie’s usual beauty routine of shaving, moisturizing and applying fake tan she notices a lump near her collarbone.
 
Although she thought it could be just a cyst she decides to get it checked out by her doctor and after several tests, she’s diagnosed with Hodgkin’s lymphoma. The video goes on to detail some of the common symptoms of the disease including fatigue, persistent lumps in the neck, armpits or groin, intensive itching, and night sweats. It explains that lymphoma is the most common cancer in people under the age of 30 and advises young people to check their neck, armpits, and groin regularly for any lumps and get anything unusual checked out by their doctor.
wmay13241
Advertisements

CD19-CAR T Cell Therapy Can Effectively Treat Non-Hodgkin’s Lymphoma

Recently, scientists at the University of Pennsylvania and Novartis reported that CD-19-CAR T cell therapy got the expected results in an early CD19 CAR-T preclinical assay involving 43 patients with non-Hodgkin’s lymphoma. These subjects were all patients with chemotherapy failure and expected survival of only about 3 months. These chemotherapy regimens include Rituximab, an antibody (first-line therapy) with B-cell antigen CD20 as the drug target. However, only 30 of the 43 subjects were successfully administered, and other patients failed to receive CD19-CAR T cell therapy due to CAR-T cell preparation failure. Among the patients successfully treated, 15 were diffuse large B cell lymphoma, 13 were follicular lymphoma, and 2 were mantle cell lymphoma.

At present the clinical trial has been carried out for about two years, and the total response rate is 47%. Six of the patients have got completely remission, and one of them did not be seen tumor recurrence in 14 months of observation. The CD19 CAR T cell therapy was most effective in follicular lymphoma with a response rate of 73%. Side effects were also expected, with only one case of lethal encephalitis, and the primary side effects were cytokine release storm (but mostly one to two level) and reversible nervous system toxicity.

Full article: http://www.digitaljournal.com/pr/3395226

The gene behind follicular lymphoma

Follicular lymphoma is an incurable cancer that affects over 200,000 people worldwide every year. A form of non-Hodgkin lymphoma, follicular lymphoma develops when the body starts making abnormal B-cells, which are white blood cells that in normal conditions fight infections. This cancer is associated with several alterations of the cell’s DNA, but it has been unclear which gene or genes are involved in its development. EPFL scientists have now analyzed the genomes of more than 200 patients with follicular lymphoma, and they discover that a gene, Sestrin1, is frequently missing or malfunctioning in FL patients. The discovery opens to new treatment options and it is now published in Science Translational Medicine.

Read more at: https://medicalxpress.com/news/2017-06-gene-follicular-lymphoma.html#jCp

wmay13241

VIDEO: CD19–directed CAR T cells shows promise in advanced lymphomas

Treatment with JCAR017 showed promise in patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma, according to the phase 1 TRANSCEND NHL trial presented at the ASCO Annual Meeting, June 2017.

Jeremy Slade Abramson, MD, clinical director of the Center for Lymphoma at Massachusetts General Hospital Cancer Center, and colleagues evaluated the safety and efficacy of JCAR017 (Juno Therapeutics) in 28 patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, grade 3B follicular lymphoma or mantle cell lymphoma.

Patients demonstrated high complete response rates. Further, toxicities appeared manageable and occurred at rates lower than those reported for other CD19–directed CAR T-cell products.

“Though our follow-up is still relatively brief, many of these remissions are proving durable and will hopefully prove curative,” Abramson said.

Next, Abramson and colleagues plan to expand the study into a pivotal population in hopes of FDA approval.

“We’re very optimistic that moving forward, we’ll see very exciting results in an ongoing way that hopefully lead this drug to being available for patients worldwide,” he added.

Video at: https://www.healio.com/hematology-oncology/lymphoma/news/online/%7B011c8992-9847-4131-8fb5-ed961149343a%7D/video-cd19directed-car-t-cells-shows-promise-in-advanced-lymphomas

wmay13241

Upcoming CAR-T coverage at Bloomberg News?

For anyone who would like to share their stories of how they were able to gain access to CAR-T therapy, or whether they are still waiting to gain access…

I received the email below a few days ago from one of the lymphoma Yahoo Groups I am a member of. I’ve since shared my CAR-T story with Michelle, but my story may be less relevant than some of yours, since I did CAR-T way back in 2015. 🙂

Please read Michelle’s email below and see if you may be interested:

Hi. I’m a journalist at Bloomberg News, and I’m writing a story about Car-T therapy for DLBCL. I am hoping to find a patient who is willing to share their story and perspective about trying to get into one of the studies or is waiting for the therapy to be approved. We and others have written about the actual treatment and how that process occurs. I want to explore the issues that come with waiting for access, as that is likely to be a bigger issue once the approach is approved. I appreciate the help!

The story will have a US focus since the approval is supposed to come this year from the FDA. I am based in Minneapolis but can call anywhere to anyone, anytime. Thanks so much for any help!

Michelle Cortez
Email: mcortez@bloomberg.net
Phone: 612-991-8887

ICML 2017 – Prof. Stephen J. Schuster from the Abramson Cancer Center, Philadelphia, PA, US, discusses interim results from the phase II JULIET trial of CTL019 in adult patients with R/R DLBCL | LymphomaHub

Dr. Schuster details the entire process using Novartis’s CTL019 CAR-T at U. Penn.

http://www.lymphomahub.com/medical-information/prof-stephen-j-schuster-interim-results-of-the-juliet-trial-of-ctl019-in-rr-dlbcl-icml-2017

As a side note, my wife and I met with Dr. Schuster and his team for over 2 hours in February 2015. I found him to be a warm, down-to-earth doctor. I almost enrolled in his trial, before my wife happened to discover online that Memorial Sloan-Kettering in NYC, where I was already a patient, had just started enrolling Follicular Lymphoma patients in their CAR-T trial. (I’ve been told I’m fNHL patient #1 to complete CAR-T at MSK.)